Clinical Features and Changes in Insulin Requirements in People with Type 2 Diabetes Requiring Insulin When Hospitalised with SARS-CoV-2 Infection
Table 1
Baseline clinical features of people with known type 2 diabetes who required initiation of insulin as a new treatment to those who did not when hospitalised with SARS-CoV-2 infection.
Insulin treatment needed (n = 39)
Insulin treatment not needed (n = 74)
value
Age, years
60 (43–86)
76 (42–97)
<0.001
Gender (male)
25 (64%)
40 (54%)
0.30
Ethnicity
Caucasian
23 (42%)
9 (33%)
0.49
Afro-Caribbean
21 (38%)
14 (52%)
0.46
Other
11 (20%)
4 (15%)
0.24
Duration of diabetes, years
11 (2–29)
8 (0–57)
0.47
HbA1c at admission, mmol/mol
63 (34–137)
52 (33–81)
0.001
HbA1c at admission, %
7.9 (5.3–14.7)
6.9 (5.1–9.6)
Oral medication for diabetes before admission
32 (82%)
46 (62%)
0.030
Previous history
Hypertension
31 (79%)
54 (73%)
0.45
Chronic kidney disease ≥ stage 3
8 (21%)
24 (32%)
0.18
Cardiovascular disease
5 (13%)
20 (27%)
0.08
Cerebrovascular disease
6 (15%)
14 (19%)
0.64
Peripheral polyneuropathy
4 (10%)
8 (11%)
0.93
Retinopathy
16 (43%)
21 (33%)
0.29
Body mass index ≥30 kg/m2
22 (73%)
14 (31%)
<0.001
Mortality
11 (28%)
21 (28%)
0.98
Admission to intensive care unit
28 (72%)
8 (11%)
<0.001
Intubation
28 (72%)
5 (7%)
<0.001
Duration of hospitalisation, days
22 (1–101)
7 (1–54)
<0.001
Data are shown as n (%) or median (range). In the full cohort of 113 people, data are available for ethnicity (n = 82), duration of diabetes (n = 97), HbA1c at admission (n = 54), and body mass index (n = 75)..
